Questions for my statistically challenged benefit.
Q1 Once the 6 mth trial became unblinded, did the placebo effect cease to be measured?
Q2. Why are new patients needed for control? Isn’t the entire population of PD pts or a random sample therefrom a control?
Q3. What about the nocebo effect? Pts who are informed of having had placebo are still subject to the nocebo effect, ie I don’t care it was a sham, I feel a benefit and will continue to release dopamine as a result.
Q4. How can any result be deemed significant one day (at 18mths) and not the next? Can the null hypothesis be so elastic?
Thx in advance for anyone willing to waste their time as I’ve just done.
u
- Forums
- ASX - By Stock
- 1AI
- Ann: NTCELL Parkinsons trial patient data 2 years after implant
Ann: NTCELL Parkinsons trial patient data 2 years after implant, page-63
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 1AI (ASX) to my watchlist
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $13.49M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 243367 | 0.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 1778841 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 243367 | 0.008 |
12 | 4919787 | 0.007 |
12 | 6066749 | 0.006 |
6 | 2510009 | 0.005 |
4 | 4065000 | 0.004 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 1778841 | 10 |
0.010 | 2702788 | 5 |
0.011 | 1490400 | 3 |
0.012 | 330000 | 2 |
0.014 | 170000 | 2 |
Last trade - 09.59am 02/09/2024 (20 minute delay) ? |
Featured News
1AI (ASX) Chart |
Day chart unavailable
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online